Biological agents in psoriatic arthritis
Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis
H.J. Johnsson1, I.B. Mcinnes2
- Institute of Infection, Immunity and Inflammation, University of Glasgow, UK. hanna.johnsson@glasgow.ac.uk
- Institute of Infection, Immunity and Inflammation, University of Glasgow, UK.
CER8919
2015 Vol.33, N°5 ,Suppl.93
PI 0115, PF 0118
Biological agents in psoriatic arthritis
Free to view
(click on article PDF icon to read the article)
PMID: 26471946 [PubMed]
Received: 31/08/2015
Accepted : 01/09/2015
In Press: 15/10/2015
Published: 16/10/2015
Abstract
The cytokines interleukin (IL)-12 and interleukin (IL)-23 have been implicated variously in the pathogenesis of psoriasis and psoriatic arthritis (PsA). By corollary, the IL-12/23 inhibitor, Ustekinumab has been developed as an approved therapeutic for the skin and musculoskeletal syndrome of psoriasis / PsA. This review describes briefly the role of IL-12 and IL-23 in the pathophysiology of psoriatic arthritis and evaluates trial data that support its clinical use in psoriasis and different manifestations of psoriatic arthritis. The next steps towards targeting this pathway also are discussed.
